کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
8716098 | 1587878 | 2018 | 25 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Five-Year Results of a Randomized Controlled Trial Comparing Effectiveness of Photodynamic Therapy, Topical Imiquimod, and Topical 5-Fluorouracil in Patients with Superficial Basal Cell Carcinoma
ترجمه فارسی عنوان
بررسی پنج ساله یک آزمایش تصادفی شده با مقایسه اثربخشی درمان فوتودینامیک، ایمیکویمود موضعی و 5-فلوروآرکایایک موضعی در بیماران مبتلا به سرطان سلول پایه ای بافتی
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
امراض پوستی
چکیده انگلیسی
For the treatment of superficial basal cell carcinoma, a prospective, noninferiority, randomized controlled multicenter trial with 601 patients showed that 5% imiquimod cream was superior and 5-fluorouracil cream not inferior to methyl aminolevulinate photodynamic therapy (MAL-PDT) at 1 and 3 years after treatment. No definite conclusion could be drawn regarding the superiority of imiquimod over 5-fluorouracil. We now present the 5-year follow-up results according to the intention-to-treat analysis. Five years after treatment, the probability of tumor-free survival was 62.7% for methyl aminolevulinate photodynamic therapy (95% confidence interval [CI]Â = 55.3-69.2), 80.5% for imiquimod (95% CIÂ = 74.0-85.6), and 70.0% for 5-fluorouracil (95% CIÂ = 62.9-76.0). The hazard ratio for treatment failure of imiquimod and 5-fluorouracil were 0.48 (95% CIÂ = 0.32-0.71, P < 0.001) and 0.74 (95% CIÂ = 0.53-1.05, PÂ = 0.09), respectively, when compared with methyl aminolevulinate photodynamic therapy. Compared with 5-fluorouracil, imiquimod showed a hazard ratio of 0.65 (95% CI 0.43-0.98, PÂ = 0.04). In conclusion, 5 years after treatment, the results of this trial show that 5% imiquimod cream is superior to both methyl aminolevulinate photodynamic therapy and 5-fluorouracil cream in terms of efficacy for superficial basal cell carcinoma. We therefore consider 5% imiquimod cream as the first choice for noninvasive treatment in most primary superficial basal cell carcinomas.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Journal of Investigative Dermatology - Volume 138, Issue 3, March 2018, Pages 527-533
Journal: Journal of Investigative Dermatology - Volume 138, Issue 3, March 2018, Pages 527-533
نویسندگان
Maud H.E. Jansen, Klara Mosterd, Aimee H.M.M. Arits, Marieke H. Roozeboom, Anja Sommer, Brigitte A.B. Essers, Han P.A. van Pelt, Patricia J.F. Quaedvlieg, Peter M. Steijlen, Patty J. Nelemans, Nicole W.J. Kelleners-Smeets,